ANO7 and prostate carcinoma: TMEM16G is highly expressed in both prostate cancer and normal prostate tissues; it is a proposed candidate for both diagnosis and immunotherapy of prostate cancer [4,73], but the detailed cellular roles of TMEM16G are not fully defined.